Home » Stocks » ARCT

Arcturus Therapeutics Holdings Inc. (ARCT)

Stock Price: $59.69 USD -2.58 (-4.14%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $59.94 +0.25 (0.42%) Jan 15, 5:41 PM
Market Cap 1.51B
Revenue (ttm) 10.27M
Net Income (ttm) -52.03M
Shares Out 22.94M
EPS (ttm) -2.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $59.69
Previous Close $62.27
Change ($) -2.58
Change (%) -4.14%
Day's Open 62.34
Day's Range 59.12 - 65.87
Day's Volume 1,610,466
52-Week Range 9.31 - 123.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 3 days ago

Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.

The Motley Fool - 1 week ago

One Wall Street analyst is very bullish about the biotech's prospects.

Benzinga - 1 week ago

Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicine...

Other stocks mentioned: TDOC, VIVO
24/7 Wall Street - 1 week ago

Over halfway through the trading day on Thursday, and the broad markets are making a run into the afternoon.

Other stocks mentioned: FDX, LMT, ROKU, ACI, BIG, CME, DDD, DPZ, EDIT
The Motley Fool - 1 week ago

The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.

Business Wire - 1 week ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BiotechShowcase--Arcturus Therapeutics to Present at Upcoming Investor Conference

Zacks Investment Research - 1 week ago

Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.

The Motley Fool - 1 week ago

This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.

Market Watch - 1 week ago

Shares of Arcturus Therapeutics Holdings Inc. gained 3.7% in premarket trading on Monday after the company said the Food and Drug Administration will allow it to move forward with a Phase 2 cl...

Business Wire - 1 week ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

Zacks Investment Research - 2 weeks ago

Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.

The Motley Fool - 2 weeks ago

Investors in fast-moving biotechs made out like bandits.

Other stocks mentioned: CODX, FLGT, INO, MRNA
Zacks Investment Research - 2 weeks ago

Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.

Business Wire - 2 weeks ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #CFTR--Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

The Motley Fool - 2 weeks ago

Two top performers fell back to earth on Tuesday.

Other stocks mentioned: BLNK
The Motley Fool - 2 weeks ago

Investors obviously considered these to be underwhelming, however.

Business Insider - 2 weeks ago

Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updat...

The Motley Fool - 2 weeks ago

The biotech announced disappointing early stage results for its single-dose COVID-19 vaccine candidate.

24/7 Wall Street - 2 weeks ago

An update on its COVID-19 vaccine candidate sent Arcturus Therapeutics Holdings Inc.

Benzinga - 2 weeks ago

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares were retreating sharply Tuesday after the company issued an update on its coronavirus vaccine program. What Happened: San Diego, Califo...

Market Watch - 2 weeks ago

Investors respond to results from a Phase 1/2 trial of its COVID-19 vaccine candidate that one analyst said were disappointing.

Business Wire - 2 weeks ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Received Approval from Singapore HSA to Proceed with Phase 2 Study of its Vaccine Candidate & Provides New/Updated Clinical/Precli...

The Motley Fool - 2 weeks ago

One's a healthcare giant. The other is a small clinical-stage biotech.

Other stocks mentioned: JNJ
The Motley Fool - 3 weeks ago

An analyst downgraded the biotech stock.

The Motley Fool - 3 weeks ago

Nothing compares to these companies.

Other stocks mentioned: JNJ, NVAX
Zacks Investment Research - 4 weeks ago

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

Other stocks mentioned: CVAC, NVAX, VXRT
The Motley Fool - 4 weeks ago

They each have a key competitive edge that could set them apart.

Other stocks mentioned: NVAX, VXRT
The Motley Fool - 1 month ago

The first to market won't necessarily dominate the market over the long run.

Other stocks mentioned: PFE
The Motley Fool - 1 month ago

Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.

Other stocks mentioned: BNTX, JNJ, MRNA, NVAX, PFE, VXRT
The Motley Fool - 1 month ago

There's something for every kind of investor with this list.

Other stocks mentioned: NVAX, PFE
The Motley Fool - 1 month ago

A biotech that no one has heard of has been making a few investors rich for much of 2020.

The Motley Fool - 1 month ago

This could be the perfect time for aggressive investors to scoop up shares.

The Motley Fool - 1 month ago

This can happen when a company holds out its hand for a big chunk of fresh capital.

Other stocks mentioned: IBIO, MRNS
Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Pricing of $150.15 Million Public Offering of Common Stock

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

The Motley Fool - 1 month ago

Don't be surprised if this small biotech takes off in 2021.

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Present at Piper Sandler's 32nd Annual Virtual Healthcare Conference

The Motley Fool - 1 month ago

Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.

Other stocks mentioned: CVAC, TBIO
The Motley Fool - 2 months ago

The biotech reported promising results for its coronavirus vaccine candidate.

Seeking Alpha - 2 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 2 months ago

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -95.74% and -26.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead f...

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 In...

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Interim ARCT-021 Phase 1/2 Study Results, and Up to $220 Million in Additional Financial Commitments from S...

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

The Motley Fool - 2 months ago

It's still really early for these two biotech stocks. But their experimental COVID-19 vaccines have tremendous potential.

Other stocks mentioned: VXRT
Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

Zacks Investment Research - 2 months ago

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for OTC Deficiency

About ARCT

Arcturus Therapeutics Holdings, an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine trans... [Read more...]

Industry
Biotechnology
Founded
2013
CEO
Joseph E. Payne M.Sc.
Employees
88
Stock Exchange
NASDAQ
Ticker Symbol
ARCT
Full Company Profile

Financial Performance

In 2019, ARCT's revenue was $20.79 million, an increase of 31.97% compared to the previous year's $15.75 million. Losses were -$25.99 million, 19.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is 96.23, which is an increase of 61.22% from the latest price.

Price Target
$96.23
(61.22% upside)
Analyst Consensus: Buy